Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13719661 | 0.94 | SMN1; SMN2 (0.35) | ACACBMAPT | |
| SCHEMBL13719855 | 0.88 | ACACB (0.37) | ACACBMAPT | |
| SCHEMBL13719960 | 0.85 | SMN1; SMN2 (0.36) | ACACBMAPT | |
| SCHEMBL13719630 | 0.84 | ACACB (0.38) | ACACB | |
| SCHEMBL13719902 | 0.84 | SMPD3 (0.34) | MAPT | |
| SCHEMBL13719545 | 0.82 | SMN1; SMN2 (0.36) | ACACBMAPT | |
| SCHEMBL13822692 | 0.81 | CCNT1 (0.35) | ACACBMAPT | |
| SCHEMBL13822696 | 0.81 | CCNT1 (0.35) | ACACBMAPT | |
| SCHEMBL13719315 | 0.81 | HTT (0.38) | MAPT | |
| SCHEMBL28070569 | 0.81 | MAPT (0.41) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2524917-B1 | FUSED PYRIDINE DERIVATIVES | SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD (CN) | 2018-06-27 | — | — | EP | disclosed |
| US-8680089-B2 | Fused pyridine derivatives | Xuanzhu Pharma Co., Ltd. (CN) | 2014-03-25 | — | — | US | disclosed |
| EP-2524917-A1 | FUSED PYRIDINE DERIVATIVES | Xuanzhu Pharmaco., Ltd. (CN) | 2012-11-21 | — | — | EP | disclosed |
| US-20120289497-A1 | FUSED PYRIDINE DERIVATIVES | Xuanzhu Pharma Co., Ltd. (CN) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289497-A1 | FUSED PYRIDINE DERIVATIVES | GPR119, INSR, IAPP | ACACB 823/4885MAPT 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.